Vertex said Daniel Brennan was appointed to its board of directors as a new member on October 20, 2026. As a result, the size of the board was increased from 10 to 11 members.

1. 01

   Vertex said Daniel Brennan was appointed to its board of directors as a new member on October 20, 2026. As a result, the size of the board was increased from 10 to 11 members.

2. 02

   The company said Brennan also joined its Audit and Finance Committee in connection with his board appointment.

3. 03

   The company said Brennan served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation from January 2014 until his retirement in June 2025, and as Senior Vice President, Corporate Controller from 2010 through 2013.

4. 04

   Vertex said Brennan received a restricted stock unit award valued at $400,000 upon joining the board on October 20, 2026, which will vest in October 2027. The company said there are no transactions involving it and Brennan that are reportable under Item 404(a) of Regulation S-K, and no arrangement or understanding between Brennan and any other person under which he was appointed to the board.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.